What New Cancer Pathway Programs Mean For The Drug Industry

New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.

By Ellen Foster Licking

The recent national coverage decision for Dendreon Corp.'s Provenge (sipuleucel-T) ought to be a wake-up call for the biopharma...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo